8,275,000 Shares Pre-Funded Warrants to Purchase 1,250,000 Shares Travere Therapeutics, Inc. UNDERWRITING AGREEMENTTravere Therapeutics, Inc. • March 1st, 2023 • Pharmaceutical preparations • New York
PRE-FUNDED COMMON STOCK PURCHASE WARRANT TRAVERE THERAPEUTICS, INC.Travere Therapeutics, Inc. • March 1st, 2023 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time on or after the Issue Date, to subscribe for and purchase from Travere Therapeutics, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is one of the Pre-Funded Common Stock Purchase Warrants issued in connection with the transactions contemplated by (i) that certain Underwriting Agreement, dated as of February 28, 2023, by and between the Company and Jefferies LLC, J.P. Morgan Securities LLC, BofA Securities, Inc. and SVB Securities LLC, as the representative of th
